Jan 05, 2021
Therapix Biosciences and Cyntar Ventures Entered a Non-Binding Letter of Intent for the Distribution of TheraPEA in Canada
Dec 08, 2020
Therapix Biosciences Announces Upgrade to OTCQB Venture Market
Dec 02, 2020
Therapix Biosciences to Collaborate with The University of Calgary to Further Examine its Proprietary Drug Candidate THX-160 for Pain
Nov 30, 2020
Therapix Biosciences Issues CEO Letter to its Shareholders
Nov 19, 2020
Therapix Biosciences Announces Pricing of $4.2 Million Offering
Aug 21, 2020
Therapix Biosciences Announces Replacement of its Board of Directors
Jul 09, 2020
Therapix Biosciences Announces OTC Pink Ticker Symbol 'TRPXY' and Removal of Injunction by Israeli Court
Jul 01, 2020
Therapix Biosciences Receives Notice of Delisting and Injunction from Israeli Court
Jun 29, 2020
Therapix Biosciences Raises $2.6 Million in Private Placement
May 19, 2020
Therapix Biosciences Closes A Joint Venture Transaction For its Sleep Indication
May 07, 2020
Therapix Biosciences Appoints Prof. Ari Shamiss (M.D., M.P.A.) to the Company's Board of Directors
Apr 28, 2020
Nasdaq Hearings Panel Grants Therapix Biosciences Extension to Regain Compliance With Listing Requirements
Apr 22, 2020
Therapix Biosciences Announces Appointment of New CEO
Apr 01, 2020
Therapix Biosciences Announces Pricing of $1.25 Million Public Offering
Mar 25, 2020
Therapix Biosciences Ltd. Announces Shareholder Conference Call
Mar 19, 2020
Therapix Biosciences Ltd. Signs Securities Purchase Agreement
Feb 27, 2020
Therapix Biosciences Ltd. Receives Nasdaq Notification Regarding Minimum Bid Requirements
Feb 06, 2020
Nasdaq Hearings Panel Grants Therapix Biosciences Extension to Regain Compliance With Listing Requirements
Dec 04, 2019
Therapix Biosciences Announces Pricing of $1,250,000 Registered Direct Offering
Dec 02, 2019
Therapix Biosciences Announces the Continued Development of THX-210 ("RESPECTRUM") Cannabinoids Based Treatment for Autism Spectrum Disorder